Edition:
United States

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

105.50EUR
11:35am EDT
Change (% chg)

€-1.00 (-0.94%)
Prev Close
€106.50
Open
€106.10
Day's High
€106.90
Day's Low
€105.10
Volume
517,892
Avg. Vol
411,786
52-wk High
€115.20
52-wk Low
€82.00

MRCG.DE

Chart for MRCG.DE

About

Merck KGaA is a Germany-based company engaged in the pharmaceutical industry. The Company operates through four business segments: Merck Serono; Consumer Health; Merck Millipore, and Performance Materials. Within the Merck Serono division, the Company focuses on therapeutic areas and prescription drugs of chemical and biotechnol... (more)

Overall

Beta: 1.04
Market Cap(Mil.): €13,945.24
Shares Outstanding(Mil.): 129.24
Dividend: 1.20
Yield (%): 1.11

Financials

  MRCG.DE Industry Sector
P/E (TTM): 28.79 29.41 30.38
EPS (TTM): 3.75 -- --
ROI: 5.65 13.85 13.36
ROE: 12.17 14.79 14.50

Merck KGaA TV crystals sales decline raises stakes for cancer drug

FRANKFURT Merck KGaA's sales of liquid crystals used in flat-screen TVs are now expected to decline this year, making the German company more reliant on its new cancer immunotherapy drug to fuel growth.

May 18 2017

UPDATE 1-Merck KGaA TV crystals sales decline raises stakes for cancer drug

* Sees 2017 adjusted earnings of 4.4 bln-4.6 bln euros (Adds analyst, CFO quotes, details on crystals, cancer drug)

May 18 2017

BRIEF-Merck KGaA says losing some market share in liquid crystals to new Chinese rivals

* CFO says seeing no signs of weakening demand at life science division

May 18 2017

Merck KGaA Q1 earnings up on lab supplies, licence prepayment

FRANKFURT, May 18 German's Merck KGaA said first-quarter adjusted core earnings rose 14.5 percent, shored up by strong demand for its biotech lab supplies and inflated by an advance drug license payment.

May 18 2017

BRIEF-German Merck's Glucophage receives label extension in UK

* Merck's Glucophage® sustained release formulation, metformin, receives label extension for patients at high risk of type 2 diabetes in UK

May 17 2017

Merck KGaA considers making divisions legally separate subsidiaries

FRANKFURT Germany's Merck KGaA is considering shifting its chemicals, healthcare and biotech supplies operations into separate subsidiaries next year to better manage its diversified businesses.

May 16 2017

UPDATE 1-Merck KGaA considers making divisions legally separate subsidiaries

* Aim would be to enhance running of diversified operations (Adds detail, rationale, spokesman)

May 16 2017

Merck KGaA considers transferring its units into subsidiaries

FRANKFURT, May 16 Germany's Merck KGaA said it was looking into shifting its diversified chemicals and healthcare businesses into separate subsidiaries next year. "The internal processes and structures shall be orientated more consequently towards the continuing growth dynamic of the sectors," the family-controlled group said in a statement on Tuesday.

May 16 2017

BRIEF-Merck KGaA's Pergoveris fertility pen gets EU approval

* Says European Commission grants approval for Merck’s new Pergoveris pen for fertility treatment Further company coverage:

May 10 2017

Pfizer immuno-oncology drug wins U.S. approval for bladder cancer

U.S. health regulators on Tuesday granted accelerated approval for Pfizer Inc's immuno-oncology drug Bavencio to treat advanced bladder cancer, marking the second approval in less than two months for the treatment developed along with Germany's Merck KGaA.

May 09 2017

More From Around the Web

Earnings vs. Estimates